5-fluoro-2-(3-hydroxy-4-methoxyphenyl)-benzothiazole | 872726-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 5-fluoro-2-(3-hydroxy-4-methoxyphenyl)-benzothiazole
• 英文别名: 5-fluoro-2-(3-hydroxy-4-methoxyphenyl)benzothiazole；5-(5-fluoro-1,3-benzothiazol-2-yl)-2-methoxyphenol
• CAS: 872726-42-6
• 化学式: C₁₄H₁₀FNO₂S
• 分子量: 275.303
• InChiKey: APSKCJVLOANIFO-UHFFFAOYSA-N

物化性质

• 熔点：
  169-172 °C
• 沸点：
  451.5±55.0 °C(Predicted)
• 密度：
  1.389±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  70.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-fluoro-2-(3-hydroxy-4-methoxyphenyl)-benzothiazole 、 间硝基苯甲酰氯 在 吡啶 作用下， 反应 2.0h， 以80%的产率得到5-fluoro-2-[3-(3-nitrobenzoyloxy)-4-methoxyphenyl]benzothiazole
  参考文献：
  名称：

  Antitumor Benzothiazoles. 26. 2-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a Simple Fluorinated 2-Arylbenzothiazole, Shows Potent and Selective Inhibitory Activity against Lung, Colon, and Breast Cancer Cell Lines

  摘要：

  A series of new 2-phenylbenzothiazoles has been synthesized on the basis of the discovery of the potent and selective in vitro antitumor properties of 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (8n; GW 610. NSC 721648). Synthesis of analogues substituted in the benzothiazole ring was achieved via the reaction of o-aminothiophenol disulfides with substituted benzaldehydes under reducing conditions. Compounds were evaluated in vitro in four human cancer cell lines, and compound 8n was found to possess exquisitely potent antiproliferative activity (GI(50) < 0.1 nM for MCF-7 and MDA 468). Potent and selective activity was also observed in the NCI 60 human cancer cell line panel. Structure-activity relationships established that the compound 8n stands on a pinnacle of potent activity, with most structural variations having a deactivating in vitro effect. Mechanistically, this new series of agents contrasts with the previously reported 2-(4-aminophenyl)benzothiazoles; compound 8n is not reliant on induction of CYP1A1 expression for antitumor activity.

  DOI：

  10.1021/jm050942k
• 作为产物：
  描述：

  1-(3-氟苯基)-2-硫脲 在 氢氧化钾 、 溴 、 对甲苯磺酸 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 23.0h， 生成 5-fluoro-2-(3-hydroxy-4-methoxyphenyl)-benzothiazole
  参考文献：
  名称：

  碳11标记的氟化2-芳基苯并噻唑类化合物的合成作为新型潜在的PET癌症显像剂。

  摘要：

  氟化的2-芳基苯并噻唑是新的潜在抗肿瘤药物，对乳腺癌，肺癌和结肠癌细胞系表现出有效的选择性抑制活性。碳11标记的氟化2-芳基苯并噻唑可作为正电子发射断层扫描（PET）成像癌症中酪氨酸激酶的新型探针。通过以下方法制备4-氟代2-芳基苯并噻唑4-氟-2-（3-苄氧基-4-甲氧基苯基）苯并噻唑（6a）和4-氟-2-（3,4-二甲氧基苯基）苯并噻唑（6b） Jacobson硫代苯胺基自由基环化化学的修饰。使用H（2）/ Pd-C对化合物6a的苄基醚基进行氢解裂解，可提供用于放射性标记的前体4-氟-2-（3-羟基-4-甲氧基苯基）苯并噻唑（7）。通过在还原条件下使邻氨基硫酚二硫化物与取代的苯甲醛反应，可以合成放射性标记的前体和参考标准的5和6氟代芳基苯并噻唑（11c-n）。目标放射性示踪剂碳11标记为4-，5-和6-氟化的芳基苯并噻唑（3-[（11）C] 6b，4-[（11）C] 11c，3-[（11）C]

  DOI：

  10.1016/j.bmc.2006.08.026

文献信息

• 2-Arylbenzothiazole derivatives
  申请人：Stevens Francis G. Malcolm

  公开号：US20060063816A1

  公开（公告）日：2006-03-23

  A compound of general structure I, wherein the compound is optionally in the form of an N-oxide or S-oxide or prodrug form and/or pharmaceutically acceptable salt thereof wherein: each of R 1 to R 9 is independently selected from hydrogen, hydroxyl, alkoxy, halo, mesyl, CX 3 (X=halo), —O(CH 2 )nNYZ—, substituted or unsubstituted lower alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; optionally R 6 and R 7 together form a dioxymethylene (—OCH 2 O—) unit and wherein n is 1 to 3 and Y and Z are independently selected from any of the following: C 1 -C 6 straight chain, branched or cyclic substituted or unsubstituted alkyl group, Y and Z can be taken together to form a cyclic alkyl or hetereoalkyl group wherein in addition to N the hetereoalkyl group comprises a heteroatom selected from N, O or S.

  通用结构I的化合物，其中该化合物可以是N-氧化物或S-氧化物或前药形式和/或其药用可接受盐形式，其中：R1至R9中的每一个独立地选择自氢、羟基、烷氧基、卤素、甲磺基、CX3（X=卤素）、—O(CH2)nNYZ—、取代或未取代的较低烷基、取代或未取代的杂烷基、取代或未取代的芳基或杂芳基，以及取代或未取代的芳基或杂芳基；可选地，R6和R7一起形成二氧亚甲基（—OCH2O—）单元，其中n为1至3，Y和Z分别选择自以下任一：C1-C6直链、支链或环状取代或未取代的烷基，Y和Z可以一起形成环状烷基或杂环烷基，其中除N外，杂环烷基还包括从N、O或S中选择的杂原子。
• 2-arylbenzothiazole derivatives
  申请人：Pharminxo Limited

  公开号：US07384966B2

  公开（公告）日：2008-06-10

  A compound of general structure I, wherein the compound is optionally in the form of an N-oxide or S-oxide or prodrug form and/or pharmaceutically acceptable salt thereof wherein: each of R1 to R9 is independently selected from hydrogen, hydroxyl, alkoxy, halo, mesyl, CX3 (X=halo), —O(CH2)nNYZ-, substituted or unsubstituted lower alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; optionally R6 and R7 together form a dioxymethylene (—OCH2O—) unit and wherein n is 1 to 3 and Y and Z are independently selected from any of the following: C1-C6 straight chain, branched or cyclic substituted or unsubstituted alkyl group, Y and Z can be taken together to form a cyclic alkyl or hetereoalkyl group wherein in addition to N the hetereoalkyl group comprises a heteroatom selected from N, O or S.

  一种一般结构为I的化合物，其中该化合物可选为N-氧化物或S-氧化物或前药形式和/或其药学上可接受的盐，其中： R1到R9中的每个独立地选择自氢、羟基、烷氧基、卤素、甲烷基磺酰基、CX3（X=卤素）、—O(CH2)nNYZ-、取代或未取代的低烷基、取代或未取代的杂烷基、取代或未取代的芳基或杂芳基、和取代或未取代的芳基烷基或杂芳基烷基；可选地，R6和R7一起形成二氧甲基（—OCH2O—）单元；其中n为1到3，Y和Z独立选择自以下任一：C1-C6直链、支链或环状取代或未取代的烷基，Y和Z可一起形成环状烷基或杂环烷基，其中除N外，杂环烷基包括从N、O或S选择的杂原子。
• Bioactivation of Fluorinated 2-Aryl-benzothiazole Antitumor Molecules by Human Cytochrome P450s 1A1 and 2W1 and Deactivation by Cytochrome P450 2S1
  作者：Kai Wang、F. Peter Guengerich

  DOI：10.1021/tx3001994

  日期：2012.8.20

  Both 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (SF 203) and 5-fluoro-2-(3,4-dimethoxyphenyl)-benzothiazole (GW 610) contain the benzothiazole pharmacophore and possess potent and selective in vitro antitumor properties. Prior studies suggested the involvement of cytochrome P450 (P450) 1A1 and 2W1-mediated bioactivation in the antitumor activities and P450 2S1-mediated deactivation of 5F 203 and GW 610. In the present study, the biotransformation pathways of 5F 203 and GW 610 by P450s 1A1, 2W1, and 2S1 were investigated, and the catalytic parameters of P450 1A1- and 2W1-catalyzed oxidation were determined in steady-state kinetic studies. The oxidations of SF 203 catalyzed by P450s 1A1 and 2W1 yielded different products, and the formation of a hydroxylamine was observed for the first time in the latter process. Liquid chromatography-mass spectrometry (LC-MS) analysis with the synthetic hydroxylamine and also a P450 2W1/5F 203 incubation mixture indicated the formation of dGuo adduct via a putative nitrenium intermediate. P450 2W1-catalyzed oxidation of GW 610 was 5-fold more efficient than the P450 1A1-catalyzed reaction. GW 610 underwent a two-step oxidation process catalyzed by P450 1A1 or 2W1: a regiospecific O-demethylation and a further hydroxylation. Glutathione (GSH) conjugates of 5F 203 and GW 610, presumably through a quninoneimine and a 1,2-quinone intermediate, respectively, were detected. These results demonstrate that human P450s 1A1 and 2W1 mediate 5F 203 and GW 610 bioactivation to reactive intermediates and lead to GSH conjugates and a dGuo adduct, which may account for the antitumor activities of 5F 203 and GW 610 and also be involved in cell toxicity. P450 2S1 can catalyze the reduction of the hydroxylamine to the amine 5F 203 under anaerobic conditions and, to a lesser extent, under aerobic conditions, thus attenuating the anticancer activity.
• US7384966B2
  申请人：——

  公开号：US7384966B2

  公开（公告）日：2008-06-10
• Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents
  作者：Min Wang、Mingzhang Gao、Bruce H. Mock、Kathy D. Miller、George W. Sledge、Gary D. Hutchins、Qi-Huang Zheng

  DOI：10.1016/j.bmc.2006.08.026

  日期：2006.12

  benzyl ether group of compound 6a using H(2)/Pd-C provided the precursor 4-fluoro-2-(3-hydroxy-4-methoxyphenyl)benzothiazole (7) for radiolabeling. Synthesis of radiolabeling precursors and the reference standards 5- and 6-fluorinated arylbenzothiazoles (11c-n) was achieved via the reaction of o-aminothiophenol disulfides with substituted benzaldehydes under reducing conditions. The target radiotracers carbon-11

  氟化的2-芳基苯并噻唑是新的潜在抗肿瘤药物，对乳腺癌，肺癌和结肠癌细胞系表现出有效的选择性抑制活性。碳11标记的氟化2-芳基苯并噻唑可作为正电子发射断层扫描（PET）成像癌症中酪氨酸激酶的新型探针。通过以下方法制备4-氟代2-芳基苯并噻唑4-氟-2-（3-苄氧基-4-甲氧基苯基）苯并噻唑（6a）和4-氟-2-（3,4-二甲氧基苯基）苯并噻唑（6b） Jacobson硫代苯胺基自由基环化化学的修饰。使用H（2）/ Pd-C对化合物6a的苄基醚基进行氢解裂解，可提供用于放射性标记的前体4-氟-2-（3-羟基-4-甲氧基苯基）苯并噻唑（7）。通过在还原条件下使邻氨基硫酚二硫化物与取代的苯甲醛反应，可以合成放射性标记的前体和参考标准的5和6氟代芳基苯并噻唑（11c-n）。目标放射性示踪剂碳11标记为4-，5-和6-氟化的芳基苯并噻唑（3-[（11）C] 6b，4-[（11）C] 11c，3-[（11）C]